385 related articles for article (PubMed ID: 15189187)
1. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.
Andrade TS; Castro LG; Nunes RS; Gimenes VM; Cury AE
Mycoses; 2004 Jun; 47(5-6):216-21. PubMed ID: 15189187
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.
Vitale RG; Perez-Blanco M; De Hoog GS
Med Mycol; 2009 Feb; 47(1):35-40. PubMed ID: 19115138
[TBL] [Abstract][Full Text] [Related]
3. In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China.
Yu J; Li R; Zhang M; Liu L; Wan Z
Med Mycol; 2008 Nov; 46(7):745-7. PubMed ID: 18608889
[TBL] [Abstract][Full Text] [Related]
4. Chromoblastomycosis in the Amazon region, Brazil, caused by Fonsecaea pedrosoi, Fonsecaea nubica, and Rhinocladiella similis: Clinicopathology, susceptibility, and molecular identification.
de Andrade TS; de Almeida AMZ; Basano SA; Takagi EH; Szeszs MW; Melhem MSC; Albuquerque M; Camargo JSAA; Gambale W; Camargo LMA
Med Mycol; 2020 Feb; 58(2):172-180. PubMed ID: 31329924
[TBL] [Abstract][Full Text] [Related]
5. [In vitro sensitivity of Paracoccidioides brasiliensis to systemically used antifungal agents].
Rodero L; Canteros CE; Rivas C; Lee W; Davel G
Rev Argent Microbiol; 1999; 31(2):78-81. PubMed ID: 10425663
[TBL] [Abstract][Full Text] [Related]
6. Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.
Coelho RA; Brito-Santos F; Figueiredo-Carvalho MHG; Silva JVDS; Gutierrez-Galhardo MC; do Valle ACF; Zancopé-Oliveira RM; Trilles L; Meyer W; Freitas DFS; Almeida-Paes R
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006675. PubMed ID: 30048450
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B.
Daboit TC; Massotti Magagnin C; Heidrich D; Czekster Antochevis L; Vigolo S; Collares Meirelles L; Alves K; Scroferneker ML
Mycoses; 2014 Feb; 57(2):116-20. PubMed ID: 23895037
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.
ZHANG JM; XI LY; ZHANG H; XIE Z; SUN JF; LI XQ; LU S
Eur J Dermatol; 2009; 19(5):451-5. PubMed ID: 19502155
[TBL] [Abstract][Full Text] [Related]
9. Chromoblastomycosis murine model and in vitro test to evaluate the sensitivity of Fonsecaea pedrosoi to ketoconazole, itraconazole and saperconazole.
Cardona-Castro N; Agudelo-Flórez P; Restrepo-Molina R
Mem Inst Oswaldo Cruz; 1996; 91(6):779-84. PubMed ID: 9283666
[TBL] [Abstract][Full Text] [Related]
10. [In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
Vivas JR; Torres-Rodríguez JM
Rev Esp Quimioter; 2001 Jun; 14(2):191-7. PubMed ID: 11704774
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and molecular identification of Fonsecaea pedrosoi strains isolated from chromoblastomycosis patients in Mexico and Venezuela.
Carolina Rojas O; León-Cachón RB; Pérez-Maya AA; Aguirre-Garza M; Moreno-Treviño MG; González GM
Mycoses; 2015 May; 58(5):267-72. PubMed ID: 25728464
[TBL] [Abstract][Full Text] [Related]
12. Chromoblastomycosis caused by Fonsecaea: clinicopathology, susceptibility and molecular identification of seven consecutive cases in Southern China.
Yang YP; Li W; Huang WM; Zhou Y; Fan YM
Clin Microbiol Infect; 2013 Nov; 19(11):1023-8. PubMed ID: 23153454
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility testing of Fonsecaea pedrosoi to antifungals.
de Bedout C; Gómez BL; Restrepo A
Rev Inst Med Trop Sao Paulo; 1997; 39(3):145-8. PubMed ID: 9460254
[TBL] [Abstract][Full Text] [Related]
14. Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.
Calvo E; Pastor FJ; Mayayo E; Hernández P; Guarro J
Antimicrob Agents Chemother; 2011 Aug; 55(8):3709-13. PubMed ID: 21576429
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Guglietta A; Palacín C; Casals J; del Valle O; Guardià C; Rodríguez V; Quindós G
Chemotherapy; 2004 Dec; 50(6):308-13. PubMed ID: 15608448
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China.
Zhang J; Xi L; Lu C; Li X; Xie T; Zhang H; Xie Z; De Hoog S
Mycoses; 2009 Mar; 52(2):176-81. PubMed ID: 18627476
[TBL] [Abstract][Full Text] [Related]
17. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.
Córdoba S; Rodero L; Vivot W; Abrantes R; Davel G; Vitale RG
Int J Antimicrob Agents; 2008 Feb; 31(2):171-4. PubMed ID: 18054469
[TBL] [Abstract][Full Text] [Related]
18. Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.
Deng S; Lei W; de Hoog GS; Yang L; Vitale RG; Rafati H; Seyedmousavi M; Tolooe A; van der Lee H; Liao W; Verweij PE; Seyedmousavi S
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581111
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
Najafzadeh MJ; Badali H; Illnait-Zaragozi MT; De Hoog GS; Meis JF
Antimicrob Agents Chemother; 2010 Apr; 54(4):1636-8. PubMed ID: 20086140
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous localized annular chromoblastomycosis.
Salgado CG; da Silva MB; Yamano SS; Salgado UI; Diniz JA; da Silva JP
J Cutan Pathol; 2009 Feb; 36(2):257-61. PubMed ID: 18727664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
